Phenotypic approaches to gene mapping in platelet function disorders Identification of new variant of P2Y12, TxA2 and GPVI receptors

Hamostaseologie

Volumn 30, Issue 1, 2010, Pages 29-38

  Watson, S ^a   Daly, M ^b   Dawood, B ^a   Gissen, P ^a   Makris, M ^b   Mundell, S ^c   Wilde, J ^a,d   Mumford, A ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Platelet dysfunction

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; THROMBOXANE A2;

BLEEDING; GENE MAPPING; GENE SEQUENCE; GENE TARGETING; GENETIC DISORDER; HEMOSTASIS; HETEROZYGOTE; HUMAN; MUTATION; PHENOTYPE; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE;

EID: 77949281858     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617145     Document Type: Review

References (55)

1. Sugiyama T et al. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 1987; 69: 1712-1720.
2. Gibbins JM et al. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett 1997; 413: 255-259.
3. Hollopeter G et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
4. Blue R et al. Application of high-throughput screening to identify a novel alpha IIb-specific small-molecule inhibitor of alpha IIb beta 3-mediated platelet interaction with fibrinogen. Blood 2008; 111: 1248-1256.
5. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008; 112: 3011-3025.
6. Ghevaert C et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood 2008; 111: 3407-3414.
7. Larson MK, Watson SP. Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3. Blood 2006; 108: 1509-1514.
8. Watkins NA et al. A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood 2009; 113: e1-e9.
9. Jones CI et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009; 114: 1405-1416.
10. Hassan AA, Kroll MH. Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program 2005: 403-408.
11. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324: 27-39.
12. Bolton-Maggs PH et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 603-633.
13. Tosetto A et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-773.
14. McKay H et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104: 159-165.
15. Bowman M et al. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7: 1418-1421.
16. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 1: 10.
17. Lanza F. Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis 2006; 1: 46.
18. Huizing M et al. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet 2008; 9: 359-386.
19. Morgan NV et al. A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). Am J Hum Genet 2006; 78: 160-166.
20. Kuijpers TW et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood 2009; 113: 4740-4746.
21. Malinin NL et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med 2009; 15: 313-318.
22. Mory A et al. Kindlin-3: a new gene involved in the pathogenesis of LAD-III. Blood 2008; 112: 2591.
23. Svensson L et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med 2009; 15: 306-312.
24. Feske S et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006; 441: 179-185.
25. Braun A et al. Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation. Blood 2009; 113: 2056-2063.
26. Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 1998; 8: 1137-1140.
27. Laffan M et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 199-217.
28. Hayward CP et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-319.
29. Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost 2009; 35: 150-157.
30. Jennings I et al. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008; 61: 950-954.
31. Cattaneo M et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7: 1029.
32. Hayward CP et al. An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thromb Haemost 2008; 100: 134-145.
33. Dawood BB, Wilde J, Watson, SP. Reference curves for aggregation and ATP secretion to aid diagnose of platelet-based bleeding disorders: effect of inhibition of ADP and thromboxane A(2) pathways. Platelets 2007; 18: 329-345.
34. Hayward CP et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 7: 676-684.
35. Quiroga T et al. Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays. Br J Haematol 2009; 147: 729-736.
36. Miller JL. Glycoprotein analysis for the diagnostic evaluation of platelet disorders. Semin Thromb Hemost 2009; 35: 224-232.
37. McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009; 35: 168-180.
38. Clauser S, Cramer-Borde E. Role of platelet electron microscopy in the diagnosis of platelet disorders. Semin Thromb Hemost 2009; 35: 213-223.
39. Snell DC et al. Differential effects of reduced glycoprotein VI levels on activation of murine platelets by glycoprotein VI ligands. Biochem J 2002; 368: 293-300.
40. Dawood B et al. Identification of a novel homo - zygous P2Y12 mutation in a patient with a mild platelet-based bleeding disorder. J Thromb Haemost 2009; 5 PP-MO-076.
41. Mumford AD et al. A novel thromboxane A2 receptor D304N variant which abrogates ligand binding in a patient with a bleeding diathesis. Blood 2009; (Epub ahead of print).
42. Goodeve A et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-121.
43. Daly ME et al. Identification of two novel P2Y12 ADP receptor gene defects in patients with type 1 von Willebrand disease. J Thromb Haemost 2009; 5 OC-MO-131.
44. Daly ME et al. Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood 2009; 113: 4110-4113
45. Fontana G et al. Haploinsufficiency of the platelet P2Y12 gene in a family with congenital bleeding diathesis. Haematologica 2009; 94: 581-584.
46. Cattaneo M et al. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000; 20: E101-E106.
47. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1: 1628-1636.
48. Shiraga M et al. Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost 2005; 3: 2315-2323.
49. Cattaneo M et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 1978-1983.
50. Remijn JA et al. Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis. Clin Chem Lab Med 2007; 45: 187-189.
51. Hirata T et al. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662-1667.
52. Fuse I et al. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity. Thromb Haemost 1996; 76: 1080-1085.
53. Higuchi W et al. Mutations of the platelet thromboxane A2 (TXA2) receptor in patients characterized by the absence of TXA2-induced platelet aggregation despite normal TXA2 binding activity. Thromb Haemost 1999; 82: 1528-1531.
54. Dumont B et al. Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations. Blood 2009; 114: 1900-1903.
55. Hermans C et al. A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder. J Thromb Haemost 2009; 7: 1356-1363.